Your SlideShare is downloading. ×
0
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Solid Cancers: An Introduction - Slide 6 - L. Licitra - Rare cancers of head and neck

802

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
802
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Head & Neck cancers Lisa Licitra Istituto Nazionale Tumori Milano
  • 2. Rare: incidence < 6/100.000 <ul><li>Nasopharyngeal cancer 0.44 </li></ul><ul><li>Nasal cavity and sinuses 0.44 </li></ul><ul><li>Salivary gland cancers 1.31 </li></ul><ul><li>Oropharyngeal cancer 2.75 </li></ul><ul><li>Oral cavity 4.79 </li></ul>
  • 3. Sinonasal tumors <ul><li>Maxillary sinus 60% </li></ul><ul><li>Ethmoid sinus 10-15% </li></ul><ul><li>Frontal sinus 1% </li></ul><ul><li>Sphenoid sinus 1% </li></ul><ul><li>Nasal cavities 20-30% </li></ul>
  • 4. WHO 2005 <ul><li>Squamous cell carcinoma (SCC) </li></ul><ul><li>Lymphoepithelial carcinoma </li></ul><ul><li>Adenocarcinoma </li></ul><ul><li>ITAC, non ITAC (tubulopapillary LG) </li></ul><ul><li>Salivary gland type carcinomas </li></ul><ul><li>Neuroendocrine tumours </li></ul><ul><li>carcinoid, small cell neuroendocrine type </li></ul><ul><li>Sinonasal undifferentiated carcinoma (SNUC) (HPV 10%)* </li></ul>El-Mofty Am J Surg Pathol 2005
  • 5. Frierson Am J Surg Pathol 1986 Ejaz Adv Anat Pathol 2005 Feature ENB SNUC SNEC Prognosis Necrosis Nuclear anaplasia Mitoses Vascular invasion Secretory granules Keratin S100 NSE variable + + variable ++ +++ + ++ +++ poor +++ +++ +++ +++ + +++ - variable favorable - - variable NR +++ ++ ++ +++
  • 6.  
  • 7. Dulgerov Cancer 2001
  • 8.  
  • 9. Head & Neck 2005
  • 10. Ganly, Head & Neck 2005
  • 11. Ganly, Head & Neck 2005
  • 12. Arch Otolaryngol H&N Surgery 2009
  • 13.  
  • 14. Hematol Oncol Clin North Am 2008
  • 15.  
  • 16.  
  • 17. SNUC Author N pts treatment outcome Levine 87 11 RT + CT 90% DOD Deutsch 93 6 CT > S (50%) + RT 33% DOD Righi 96 7 S (50%) + RT + CT 60% DOD Gorelick 00 4 S (100%) + RT + CT 90% DOD Kim 04 8 S (50%) + RT + CT 75% DOD Kramer 04 4 S (100%) + RT + CT 0 % DOD Chen 08 21 S (90%) + RT + CT 57 % DOD
  • 18. 40% DOD S + RT or RT + CT 15 Tanzler 08 65% DOD CT+ RT + S or CT + RT 20 Musy 02 40% DOD CT + RT/CT or S + RT/CT 10 Rischin 04 62,5% 5yr OS S (50%) + RT + CT or CT + S or RT 16 Rosenthal 04 50% DOD S + RT + CT 14 Miyamoto 00 outcome treatment N pts Author
  • 19. Dulgerov Lancet Oncology 2001
  • 20. Head & Neck 2008
  • 21.  
  • 22.  
  • 23.  
  • 24. Arch Otolaryngol Head and Neck Surg, 2001
  • 25. Hanna Arch Otolaryngol H&N Surg 2011
  • 26.  
  • 27.  
  • 28. Conclusions <ul><li>WHO classification </li></ul><ul><li>Multimodal therapeutic approach that includes surgery, radiation and histotype driven chemotherapy </li></ul><ul><li>Biology to be exploited </li></ul>
  • 29.  
  • 30. IARC 2009
  • 31. Etiologic heterogeneity of OSCCs Adapted from Gillison ML. Seminars in Oncology, 2004 HPV-induced OSCCs Tobacco/alcohol-induced OSCCs
  • 32. Smeets SJ Oncogene 2006
  • 33. JNCI, 2000
  • 34. HPV as a prognostic factor Gillison, JNCI 2000
  • 35. HPV in H&N cancer: systematic review Kreimer A, 2005
  • 36.  
  • 37. HPV-R HPV-U
  • 38. Hematol Oncol Clin N Am 2008
  • 39. Risk factors HPV + SCC <ul><li>Sexual behaviour </li></ul><ul><li>HPV exposure </li></ul><ul><li>Marijuana consumption </li></ul>
  • 40. Oral Oncology 2007
  • 41. HPV pos H&N and stage… Study N pts Subsite % HPV Advanced stage for HPV + Gillison, 00 252 H&N 25 not relevant (N) Mellin, 00 34 oroph 41 not relevant (stage) Schwartz, 01 254 H&N 15 for N and stage Lindel, 01 99 oroph 14 not relevant (T and N) Ritchie, 03 128 oral + oroph 21 for stage IV Weinberger, 06 79 oroph 61 for N (HPV + p16) Licitra, 06 90 oroph 19 not relevant (stage)
  • 42. HPV-pos H&N cause-specific survival Study N pts Subsite % HPV TX HR Gillison, 00 252 H&N 25 Surg and/or RT 0.40 Mellin, 01 34 oroph 41 RT (100%) + Surg (45%) 0.50 Schwartz, 01 254 H&N 15 Surg and/or RT 0.17 Lindel, 01 99 oroph 14 RT + CT 0.35 Ritchie, 03 128 oral + oroph 21 Surg and/or RT 0.30 Weinberger, 06 79 oroph 61 RT (100%) + Surg (40 %) ------ Licitra, 06 90 oroph 19 Surg (100%) + RT (66%) 0.26
  • 43.  
  • 44.  
  • 45. RTOG 0129 <ul><li>SFRT+ CDDP x 3 </li></ul><ul><li>AFX-c + CDDP x 2 </li></ul><ul><li>433/721 Oropharynx </li></ul><ul><li>323 HPV determination </li></ul><ul><li>198 HPV 16 + </li></ul><ul><li>ISH & p16 IHC </li></ul>
  • 46. Ang K NEJM 2010
  • 47.  
  • 48. 22% vs 43% 38% vs 30% 40% vs 27%
  • 49.  
  • 50. Fisher CA Annals Oncol 2010
  • 51.  
  • 52. Gold standard (?) tumor HPV detection <ul><li>Traditional PCR too sensitive </li></ul><ul><li>Quantitative viral DNA or mRNA PCR more precise </li></ul><ul><li>ISH not completely sensitive </li></ul><ul><li>p16 is a surrogate marker </li></ul>
  • 53. P16 positive tumors HPV + HPV - ANG KK 2010
  • 54.  
  • 55. P16 neg =15 pts 5 non funct mut; 3 overexpr EGFR; overexp cyclin D1; 1 PI3KA mut; 1 gene copy number
  • 56. R&M: OS as function of HPV positivity 24 pts 72 pts
  • 57. Clinical trial strategies <ul><li>Different therapeutic options for HPV+ and HPV- oropharyngeal SCCs </li></ul><ul><li>Among HPV + risk based enrolment </li></ul><ul><li>Need for HPV detection standardisation </li></ul>
  • 58. WHO 2005 <ul><li>Acinic cell carcinoma </li></ul><ul><li>Mucoepidermoid carcinoma </li></ul><ul><li>Adenoid cystic carcinoma </li></ul><ul><li>Polymorphous low-grade adenocarcinoma </li></ul><ul><li>Epithelial-myoepithelial carcinoma </li></ul><ul><li>Clear cell carcinoma, NOS </li></ul><ul><li>Basal cell adenocarcinoma </li></ul><ul><li>Sebaceous carcinoma </li></ul><ul><li>Sebaceous lymphadenocarcinoma </li></ul><ul><li>Cystadenocarcinoma </li></ul><ul><li>Low-grade cribriform cystadenocarcinoma </li></ul><ul><li>Mucinous adenocarcinoma </li></ul><ul><li>Oncocytic carcinoma </li></ul><ul><li>Salivary duct carcinoma </li></ul><ul><li>Adenocarcinoma, NOS </li></ul><ul><li>Myoepithelial carcinoma </li></ul><ul><li>Carcinoma ex pleomorphic adenoma </li></ul><ul><li>Carcinosarcoma </li></ul><ul><li>Metastatizing pleomorphic adenoma </li></ul><ul><li>Squamous cell carcinoma </li></ul><ul><li>Small cell carcinoma </li></ul><ul><li>Large cell carcinoma </li></ul><ul><li>Lymphoepithelial carcinoma </li></ul><ul><li>Sialoblastoma </li></ul>
  • 59. High risk tumors … <ul><li>SDC </li></ul><ul><li>MCC: grading </li></ul><ul><li>ACC: staging (bone), hist. pattern (solid component > 30%), surg margins </li></ul><ul><li>AdC: grading </li></ul><ul><li>MC: grading </li></ul><ul><li>Acinic Cell C: submandibular origin, staging </li></ul><ul><li>EMC recurrence 40% </li></ul>
  • 60. TREATMENT <ul><li>Optimal surgery : </li></ul><ul><li>Gross total tumor resection </li></ul><ul><li>Elective neck dissection is reserved for high grade and/or advanced-stage disease </li></ul><ul><li>Facial nerve function preservation surgery whenever feasible </li></ul><ul><li>PORT is reserved for high grade and/or advanced-stage disease, R1 resections, recurrent benign tumors </li></ul><ul><li>Unresectable/inoperable locoregional disease hadrotherapy is promising </li></ul>
  • 61. Schulz-Ertner D Cancer 2005 ACC RT + Carbonion RT
  • 62. Lung metastasectomy in ACC : selection criteria <ul><li>R0 resection </li></ul><ul><li>< 6 metastases </li></ul><ul><li>DFI > 36 months </li></ul>
  • 63. Locati L 2005 OS FFP OS
  • 64. Laurie & Licitra J Clin Oncol 2006
  • 65. <ul><li>Impact on OS not yet demonstrated </li></ul><ul><li>RR > at localregional level </li></ul><ul><li>Impact on QoL possibile </li></ul>Results of chemo …
  • 66. Locati L Oral Oncology 2009
  • 67. Biological agents in recurrent/mts SGCs Author Study PTS Treatment Outcome Glisson 05 Ph II 29 Gefitinib 250 RR 0 Agulnik 06 Licitra 06 Hotte 05 Ph II Ph II Ph II 38 30 16 Lapatinib 1500 Cetuximab Imatinib 400 RR 0 RR 0 RR 0 Pfeffer 06 Argiris 06 Ph II Ph II 10 25 Imatinib 400 - 800 Bortezomib RR 0 RR 0
  • 68. HORMONAL TREATMENT IN RELAPSED AR-EXPRESSING PAROTID ADENOCARCINOMA At treatment beginning…… Two months later…..
  • 69. 2010
  • 70. A J Surg Pathol 2010

×